Cargando…

Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients

Despite some significant therapeutic breakthroughs leading to immunotherapy, a high percentage of patients with non-small cell lung cancer (NSCLC) do not respond to treatment on relapse, thus experiencing poor prognosis and survival. The unsatisfying results could be related to the features of the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baci, Denisa, Cekani, Elona, Imperatori, Andrea, Ribatti, Domenico, Mortara, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298844/ https://www.ncbi.nlm.nih.gov/pubmed/35874749 http://dx.doi.org/10.3389/fimmu.2022.914890

Ejemplares similares

Editorial: The intricate innate immune-cancer cell relationship in the context of tumor angiogenesis, immunity and microbiota: The angiogenic switch in the tumor microenvironment as a key target for immunotherapies
por: Mortara, Lorenzo, et al.
Publicado: (2022)

Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
por: Bruno, Antonino, et al.
Publicado: (2019)

Innate Immunity Effector Cells as Inflammatory Drivers of Cardiac Fibrosis
por: Baci, Denisa, et al.
Publicado: (2020)

Microbiome and Prostate Cancer: A Novel Target for Prevention and Treatment
por: Kustrimovic, Natasa, et al.
Publicado: (2023)

Innate Immune Response Regulation by the Human RNASET2 Tumor Suppressor Gene
por: Acquati, Francesco, et al.
Publicado: (2019)

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
por: Cekani, Elona, et al.
Publicado: (2022)

Prostate Cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors
por: Gallazzi, Matteo, et al.
Publicado: (2021)

Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects
por: Bassani, Barbara, et al.
Publicado: (2019)

The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
por: Baci, Denisa, et al.
Publicado: (2020)

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
por: Albini, Adriana, et al.
Publicado: (2018)

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease
por: Zhang, Lingling, et al.
Publicado: (2018)

The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis
por: Ma, Jia-Chun, et al.
Publicado: (2022)

Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
por: Zhou, Suna, et al.
Publicado: (2023)

Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer
por: Ge, Yang, et al.
Publicado: (2023)

Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

A SIRPαFc Fusion Protein Conjugated With the Collagen-Binding Domain for Targeted Immunotherapy of Non-Small Cell Lung Cancer
por: Liu, Jiayang, et al.
Publicado: (2022)

Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report
por: Llanos, Anabella, et al.
Publicado: (2012)

Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer
por: Wang, Yuchang, et al.
Publicado: (2022)

Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy
por: Velez, Antonio, et al.
Publicado: (2023)

How Does Vitamin D Affect Immune Cells Crosstalk in Autoimmune Diseases?
por: Gallo, Daniela, et al.
Publicado: (2023)

Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
por: Li, Shumin, et al.
Publicado: (2020)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
por: Meng, Lu, et al.
Publicado: (2021)

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
por: Shen, Jie, et al.
Publicado: (2023)

The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective
por: Liang, Shuai, et al.
Publicado: (2023)

Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?
por: Parisi, Luca, et al.
Publicado: (2018)

To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations
por: Cai, Ruoxue, et al.
Publicado: (2023)

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis
por: Li, Shuling, et al.
Publicado: (2022)

Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
por: Wu, Yijun, et al.
Publicado: (2022)

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
por: Jie, Chen, et al.
Publicado: (2023)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies
por: Baci, Denisa, et al.
Publicado: (2019)

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
por: Shi, Chunyan, et al.
Publicado: (2022)

Erratum: Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
Publicado: (2022)

De novo priming: driver of immunotherapy responses or epiphenomenon?
por: Young, Alexander L., et al.
Publicado: (2023)

Trypanosoma cruzi extracellular amastigotes and host cell signaling: more pieces to the puzzle
por: Ferreira, Éden R., et al.
Publicado: (2012)

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Yang, Guanqun, et al.
Publicado: (2022)

Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Wu, Min, et al.
Publicado: (2021)

The Drivers of Pathology in Zoonotic Avian Influenza: The Interplay Between Host and Pathogen
por: Horman, William S. J., et al.
Publicado: (2018)

Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy
por: Mortara, Lorenzo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ap5bbqdenf1l3alo83u6b3bim2